{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T04:09:38Z","timestamp":1781928578386,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T00:00:00Z","timestamp":1370390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00213-013-3154-1","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T07:40:15Z","timestamp":1370331615000},"page":"175-185","source":"Crossref","is-referenced-by-count":37,"title":["A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder"],"prefix":"10.1007","volume":"228","author":[{"given":"Hiroyoshi","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,5]]},"reference":[{"key":"3154_CR1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2710.2008.00996.x","volume":"34","author":"J Adan-Manes","year":"2009","unstructured":"Adan-Manes J, Garcia-Parajua P (2009) Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 34:245\u2013246","journal-title":"J Clin Pharm Ther"},{"key":"3154_CR2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4088\/JCP.v68n0522h","volume":"68","author":"N Ahuja","year":"2007","unstructured":"Ahuja N, Lloyd AJ (2007) Aripiprazole and worsening of psychosis: a case report. J Clin Psychiatry 68:805\u2013806","journal-title":"J Clin Psychiatry"},{"key":"3154_CR3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.4088\/JCP.v61n0910","volume":"61","author":"JM Aubry","year":"2000","unstructured":"Aubry JM, Simon AE, Bertschy G (2000) Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry 61:649\u2013655","journal-title":"J Clin Psychiatry"},{"key":"3154_CR4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JCP.0b013e3182223b13","volume":"31","author":"J Avari","year":"2011","unstructured":"Avari J, Mahgoub N, Alexopoulos GS (2011) Adding aripiprazole to clozapine worsened delusions and hallucinations: a case report. J Clin Psychopharmacol 31:528\u2013531","journal-title":"J Clin Psychopharmacol"},{"key":"3154_CR5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.4088\/JCP.v66n1019h","volume":"66","author":"ME Barnas","year":"2005","unstructured":"Barnas ME, Hussain N, Petrides G (2005) Treatment-emergent psychosis with aripiprazole. J Clin Psychiatry 66:1339","journal-title":"J Clin Psychiatry"},{"key":"3154_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/13651501.2011.605957","volume":"16","author":"A Benyamina","year":"2012","unstructured":"Benyamina A, Samalin L (2012) Atypical antipsychotic-induced mania\/hypomania: a review of recent case reports and clinical studies. Int J Psychiatry Clin Pract 16:2\u20137","journal-title":"Int J Psychiatry Clin Pract"},{"key":"3154_CR7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10401230600614678","volume":"18","author":"MJ Burke","year":"2006","unstructured":"Burke MJ, Lincoln J (2006) Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Ann Clin Psychiatry 18:129\u2013130","journal-title":"Ann Clin Psychiatry"},{"key":"3154_CR8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381\u2013389","journal-title":"J Pharmacol Exp Ther"},{"key":"3154_CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pnpbp.2010.10.008","volume":"35","author":"YH Chiu","year":"2011","unstructured":"Chiu YH, Chen CH, Lu ML (2011) Worsening psychosis after adding aripiprazole to clozapine. Prog Neuropsychopharmacol Biol Psychiatry 35:291\u2013292","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3154_CR10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4088\/JCP.08l04528","volume":"70","author":"DY Cho","year":"2009","unstructured":"Cho DY, Lindenmayer JP (2009) Aripiprazole-induced agitation after clozapine discontinuation: a case report. J Clin Psychiatry 70:141\u2013143","journal-title":"J Clin Psychiatry"},{"key":"3154_CR11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","volume":"26","author":"A DeLeon","year":"2004","unstructured":"DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649\u2013666","journal-title":"Clin Ther"},{"key":"3154_CR12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4088\/JCP.v65n0122b","volume":"65","author":"JR DeQuardo","year":"2004","unstructured":"DeQuardo JR (2004) Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? J Clin Psychiatry 65:132\u2013133","journal-title":"J Clin Psychiatry"},{"key":"3154_CR13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2515\/therapie:2008019","volume":"63","author":"C Ducroix","year":"2008","unstructured":"Ducroix C, Beghelli F, Rousset I, Vacheron MN (2008) Emergent mania with atypical antipsychotics: review of the literature about one case. Therapie 63:153\u2013154","journal-title":"Therapie"},{"key":"3154_CR14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","volume":"13","author":"WW Fleischhacker","year":"2010","unstructured":"Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13:1115\u20131125","journal-title":"Int J Neuropsychopharmacol"},{"key":"3154_CR15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O\u2019Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686\u2013693","journal-title":"Am J Psychiatry"},{"key":"3154_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.jcp.0000196417.44847.0b","volume":"26","author":"ID Glick","year":"2006","unstructured":"Glick ID, Duggal V, Hodulik C (2006) Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clin Psychopharmacol 26:101\u2013103","journal-title":"J Clin Psychopharmacol"},{"key":"3154_CR17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4088\/PCC.v08n0611e","volume":"8","author":"S Grover","year":"2006","unstructured":"Grover S, Sharan P, Gupta N (2006) Aripiprazole worsens psychosis: a case report. Prim Care Companion J Clin Psychiatry 8:380\u2013381","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"3154_CR18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00213-003-1672-y","volume":"171","author":"GE Jaskiw","year":"2004","unstructured":"Jaskiw GE, Popli AP (2004) A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications. Psychopharmacology (Berl) 171:365\u2013374","journal-title":"Psychopharmacology (Berl)"},{"key":"3154_CR19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.4088\/JCP.v68n0919c","volume":"68","author":"ND Kapusta","year":"2007","unstructured":"Kapusta ND, Mossaheb N, Barnas C, Fischer P (2007) Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration. J Clin Psychiatry 68:1445\u20131446","journal-title":"J Clin Psychiatry"},{"key":"3154_CR20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1592\/phco.27.9.1339","volume":"27","author":"JW Lea","year":"2007","unstructured":"Lea JW, Stoner SC, Lafollette J (2007) Agitation associated with aripiprazole initiation. Pharmacotherapy 27:1339\u20131342","journal-title":"Pharmacotherapy"},{"key":"3154_CR21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/13651501.2011.644300","volume":"16","author":"M Letmaier","year":"2012","unstructured":"Letmaier M, Painold A, Holl AK, Grohmann R, Vergin H (2012) Severe psychotic exacerbation during combined treatment with aripiprazole\/haloperidol after prior treatment with risperidone. Int J Psychiatry Clin Pract 16:153\u2013156","journal-title":"Int J Psychiatry Clin Pract"},{"key":"3154_CR22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","volume":"91","author":"JA Lieberman","year":"1987","unstructured":"Lieberman JA, Kane JM, Alvir J (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91:415\u2013433","journal-title":"Psychopharmacology (Berl)"},{"key":"3154_CR23","first-page":"409","volume":"32","author":"HC Lin","year":"2009","unstructured":"Lin HC, Chong MY, Lee Y, Yeh WC, Lin PY (2009) Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung Med J 32:409\u2013416","journal-title":"Chang Gung Med J"},{"key":"3154_CR24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","volume":"61","author":"SR Marder","year":"2003","unstructured":"Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123\u2013136","journal-title":"Schizophr Res"},{"key":"3154_CR25","doi-asserted-by":"crossref","unstructured":"Michalopoulou PG, Lykouras L (2006) Manic\/hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 30:549\u2013564","DOI":"10.1016\/j.pnpbp.2005.11.026"},{"key":"3154_CR26","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"3154_CR27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","volume":"114","author":"J Moncrieff","year":"2006","unstructured":"Moncrieff J (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114:3\u201313","journal-title":"Acta Psychiatr Scand"},{"key":"3154_CR28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","volume":"69","author":"JW Newcomer","year":"2008","unstructured":"Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L\u2019Italien GJ, Nys M, Carson WH, McQuade RD (2008) A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 69:1046\u20131056","journal-title":"J Clin Psychiatry"},{"key":"3154_CR29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1176\/appi.ajp.164.1.172-a","volume":"164","author":"PR Padala","year":"2007","unstructured":"Padala PR, Wengel SP, Petty F (2007) Manic episode during treatment with aripiprazole. Am J Psychiatry 164:172\u2013173","journal-title":"Am J Psychiatry"},{"key":"3154_CR30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1590\/S1516-44462007000100028","volume":"29","author":"MP Ponde","year":"2007","unstructured":"Ponde MP, Novaes CM (2007) Aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia. Rev Bras Psiquiatr 29:92","journal-title":"Rev Bras Psiquiatr"},{"key":"3154_CR31","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4088\/JCP.v65n1116","volume":"65","author":"F Rachid","year":"2004","unstructured":"Rachid F, Bertschy G, Bondolfi G, Aubry JM (2004) Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 65:1537\u20131545","journal-title":"J Clin Psychiatry"},{"key":"3154_CR32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1017\/S1461145706006523","volume":"10","author":"M Raja","year":"2007","unstructured":"Raja M (2007) Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 10:107\u2013110","journal-title":"Int J Neuropsychopharmacol"},{"key":"3154_CR33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-200401000-00009","volume":"19","author":"S Ramaswamy","year":"2004","unstructured":"Ramaswamy S, Vijay D, William M, Sattar SP, Praveen F, Petty F (2004) Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 19:45\u201348","journal-title":"Int Clin Psychopharmacol"},{"key":"3154_CR34","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1176\/appi.ajp.161.7.1308","volume":"161","author":"RR Reeves","year":"2004","unstructured":"Reeves RR, Mack JE (2004) Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 161:1308","journal-title":"Am J Psychiatry"},{"key":"3154_CR35","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","volume":"164","author":"JC Shim","year":"2007","unstructured":"Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164:1404\u20131410","journal-title":"Am J Psychiatry"},{"key":"3154_CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","volume":"152","author":"S Silvestri","year":"2000","unstructured":"Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174\u2013180","journal-title":"Psychopharmacology (Berl)"},{"key":"3154_CR37","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","volume":"168","author":"TS Stroup","year":"2011","unstructured":"Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168:947\u2013956","journal-title":"Am J Psychiatry"},{"key":"3154_CR38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0b013e3181accfec","volume":"29","author":"H Takeuchi","year":"2009","unstructured":"Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H (2009) Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. J Clin Psychopharmacol 29:394\u2013395","journal-title":"J Clin Psychopharmacol"},{"key":"3154_CR39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-2006-951609","volume":"40","author":"R Traber","year":"2007","unstructured":"Traber R, Schneiter R, Modestin J (2007) A case of aripiprazole-induced mania. Pharmacopsychiatry 40:37\u201338","journal-title":"Pharmacopsychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-013-3154-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-013-3154-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-013-3154-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T12:36:27Z","timestamp":1558614987000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-013-3154-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["3154"],"URL":"https:\/\/doi.org\/10.1007\/s00213-013-3154-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,5]]}}}